These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 8620409

  • 1. Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Kornek G, Raderer M, Schenk T, Pidlich J, Schulz F, Globits S, Tetzner C, Scheithauer W.
    Cancer; 1995 Oct 15; 76(8):1356-62. PubMed ID: 8620409
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Scheithauer W, Kornek G, Raderer M, Koperna-Mach K, Müller C, Karner J, Kastner J, Tetzner C.
    J Cancer Res Clin Oncol; 1995 Oct 15; 121 Suppl 3():R7-10. PubMed ID: 8698741
    [Abstract] [Full Text] [Related]

  • 3. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Murphy RF, Hamilton JM, Balis F, Steinberg S, Arbuck SG, Setser A, Jordan E, Chen A.
    J Clin Oncol; 1994 Mar 15; 12(3):560-8. PubMed ID: 8120554
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Scheithauer W, Kornek GV, Raderer M, Hejna M, Valencak J, Miholic J, Kovats E, Lang F, Funovics J, Bareck E, Depisch D.
    Br J Cancer; 1999 Aug 15; 80(11):1797-802. PubMed ID: 10468299
    [Abstract] [Full Text] [Related]

  • 5. Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
    Paccagnella A, Favaretto A, Riccardi A, Danova M, Ghiotto C, Giordano M, Pappagallo G, Comis S, Panozzo M, Chieco-Bianchi L.
    Cancer; 1993 Aug 01; 72(3):697-706. PubMed ID: 8392903
    [Abstract] [Full Text] [Related]

  • 6. Phase I dose intensification study of 2-weekly epirubicin with GM-CSF in advanced cancer.
    Michael M, Toner GC, Olver IN, Fenessy A, Bishop JF.
    Am J Clin Oncol; 1997 Jun 01; 20(3):259-62. PubMed ID: 9167749
    [Abstract] [Full Text] [Related]

  • 7. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL, Palackdharry CS, Padavic K, Haas N, Kilpatrick D, Langer C, Comis R.
    J Clin Oncol; 1994 Jun 01; 12(6):1251-8. PubMed ID: 8201386
    [Abstract] [Full Text] [Related]

  • 8. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
    Becerra CR, Verma UN, Tran HT, Tavana D, Williams NS, Frenkel EP.
    Am J Clin Oncol; 2008 Jun 01; 31(3):219-25. PubMed ID: 18525298
    [Abstract] [Full Text] [Related]

  • 9. Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.
    Talbot SM, Westerman DA, Grigg AP, Toner GC, Wolf M, Bishop J, McKendrick J, Zalcberg J, Levi J, Fox RM, Green MD.
    Ann Oncol; 1999 Aug 01; 10(8):907-14. PubMed ID: 10509151
    [Abstract] [Full Text] [Related]

  • 10. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM, Ratain MJ, Van Echo DA, Rosner G, Egorin MJ, Budman DR, Vogelzang NJ, Norton L, Schilsky RL.
    J Natl Cancer Inst; 1993 Aug 18; 85(16):1319-26. PubMed ID: 8340944
    [Abstract] [Full Text] [Related]

  • 11. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S, Lauria R, Carlomagno C, Perrone F, De Laurentiis M, Gallo C, Martignetti A, Bellelli T, Limite G, Petrella G, Bianco AR.
    Int J Oncol; 1999 Aug 18; 15(2):339-46. PubMed ID: 10402245
    [Abstract] [Full Text] [Related]

  • 12. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
    Huisman C, Biesma B, Postmus PE, Giaccone G, Schramel FM, Smit EF.
    Br J Cancer; 2001 Nov 16; 85(10):1456-61. PubMed ID: 11720428
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
    Luikart SD, Herndon JE, Hollis DR, MacDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H, Green MR.
    Am J Clin Oncol; 1997 Feb 16; 20(1):24-30. PubMed ID: 9020283
    [Abstract] [Full Text] [Related]

  • 14. Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
    Venturini M, Del Mastro L, Testore F, Danova M, Garrone O, Lanfranco C, Latini F, Sertoli MR, Lionetto R, Queirolo P, Ardizzoni A, Rosso R.
    Cancer Chemother Pharmacol; 1996 Feb 16; 38(6):487-94. PubMed ID: 8823488
    [Abstract] [Full Text] [Related]

  • 15. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C, Vallejos C.
    J Clin Oncol; 1998 Jul 16; 16(7):2352-8. PubMed ID: 9667250
    [Abstract] [Full Text] [Related]

  • 16. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma.
    Partyka S, Dumas P, Ajani J.
    Cancer; 1999 Jun 01; 85(11):2336-9. PubMed ID: 10357402
    [Abstract] [Full Text] [Related]

  • 17. Mitomycin C, vinorelbine, carboplatin plus granulocyte-macrophage colony-stimulating factor for treatment of advanced non-small cell lung carcinoma.
    Hejna M, Kornek GV, Raderer M, Marosi L, Schneeweiss B, Greul R, Weinländer G, Valencak J, Huber H, Scheithauer W.
    Oncology; 1998 Jun 01; 55(6):538-42. PubMed ID: 9778620
    [Abstract] [Full Text] [Related]

  • 18. A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
    Fernandez MC, Krailo MD, Gerbing RR, Matthay KK.
    Cancer; 2000 Jun 15; 88(12):2838-44. PubMed ID: 10870069
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G, Spielmann M, Dieras V, Tubiana-Hulin M, Bonneterre J, Pouillart P, Kayitalire L, Guastalla JP, Graffand N, Garet F, Dumortier A, Pellae-Cosset B.
    Semin Oncol; 1997 Feb 15; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.